Daptomycin Market

Market CAGR for Daptomycin is being driven by the rising number of people with skin and skin structure infections, its growing use as an antibacterial drug, a bacterial metabolite, and a calcium-dependent antibiotic, rising bloodstream infections like sepsis, the availability of pharmaceuticals, and the prevalence of improved healthcare infrastructure are some of the vital and significant factors that are likely to propel the daptomycin market’s growth in the anticipated period. Bloodstream infections are infective endocarditis, primary bacteremia, central venous catheter-associated bloodstream infections, and those secondary bacteremia owed to focal infections such as osteomyelitis, abscesses, urinary tract infection, or pneumonia.

An infectious pathogen spreads the bloodstream by direct invasion into blood vessels via lymphatic vessels, draining a focus of infection such as an abscess or through vascular devices such as needless catheters.  Extreme shivering or muscle pain, Slurred speech or confusion, oliguria, respiratory problems, and pale skin with falling blood pressure are all symptoms potentially related to initial sepsis. Bloodstream infections (BSIs) are extremely severe human infections with markedly high morbidity and mortality rates.

Additionally, an increase in R&D activities and the adoption of supportive reimbursement policies will further contribute by creating enormous chances to drive the expansion of the daptomycin market throughout the projected period.  For Instance In May 2021, as per clinicaltrials.gov., Ceftobiprole Medocarial under Phase III trials demonstrated an effective treatment option for acute bacterial skin and skin structure infections. The new antibiotic NUZYRA (omadacycline), which comes in oral and intravenous (IV) formulations, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of skin structure infections and community-acquired bacterial pneumonia.

As per Annals of Cardiothoracic Surgery, Right-sided infective endocarditis (RSIE) is less communal than left-sided infective endocarditis (IE), which is only 5% to 10% of cases of IE. Endocarditis affecting the right heart chambers and valves has typical etiologies, epidemiology, and unique diagnostics and therapeutic options. Right-sided infection endocarditis is due to venous drug abuse. Right-sided infective endocarditis associated to drug abuse mostly affects the tricuspid and rarely the pulmonary valves. As per Intech Open, a study in the U.S., North Carolina, reported a 12-fold rise in hospitalizations for intravenous drug use-related IE over the last decade.

Right-sided infective endocarditis (RSIE) can be classified into three epidemiological groups intravascular device carriers, intravenous drug users (IDUs), and the ‘three noses’ group, which is no left-sided device or IDUs.

Daptomycin has been used successfully for treating several types of bacterial infections, including acute respiratory tract infection (ARTI), skin & soft tissue infection (SSTI), and bone & joint infection (BJIs) due to its strong and bacterial properties against various microorganisms including methicillin-resistant Staphylococcus aureus (MRSA). This factor, coupled with rising prevalence rates of BJIs across developed countries such as Germany and France, will boost demand over the forecast period. For Instance Thus, driving the Daptomycin market revenue.

The Global Daptomycin Market Industry is projected to experience robust growth, with estimates indicating a market value of 3.32 USD Billion in 2024 and an increase to 4.74 USD Billion by 2035. This growth is underpinned by a CAGR of 3.28% from 2025 to 2035, reflecting the increasing demand for effective antibiotic therapies. The projections highlight the industry's potential to adapt to evolving healthcare needs and the ongoing challenges posed by antibiotic resistance, thereby ensuring a sustained market presence.

The global demographic shift towards an aging population significantly impacts the demand for Daptomycin, as older adults are more susceptible to bacterial infections. This trend is particularly evident in developed regions, where the geriatric population is projected to rise substantially. The Global Daptomycin Market Industry is likely to experience increased demand as healthcare systems adapt to the needs of this demographic. The anticipated growth in market value underscores the importance of addressing the healthcare challenges posed by an aging society, thereby enhancing the relevance of Daptomycin in clinical practice.

The ongoing expansion of healthcare infrastructure in emerging economies plays a crucial role in the growth of the Global Daptomycin Market Industry. As healthcare facilities improve and access to advanced medical treatments increases, the demand for effective antibiotics like Daptomycin is likely to rise. This trend is particularly pronounced in regions with previously limited access to such therapies. The market's growth trajectory reflects the broader improvements in healthcare delivery systems, which are essential for addressing the rising burden of bacterial infections.

The increasing prevalence of bacterial infections globally drives the demand for effective antibiotics, including Daptomycin. As antibiotic resistance continues to pose a significant challenge, healthcare providers are increasingly turning to Daptomycin for its efficacy against resistant strains. The Global Daptomycin Market Industry is expected to witness substantial growth, with projections indicating a market value of 3.32 USD Billion in 2024. This trend reflects a broader shift towards advanced therapeutic options in the face of rising infection rates, thereby enhancing the market's potential.

Heightened awareness regarding antibiotic resistance among healthcare professionals and patients contributes to the growth of the Global Daptomycin Market Industry. As the medical community emphasizes the importance of using effective antibiotics, Daptomycin emerges as a preferred choice for treating complicated skin and soft tissue infections. The market is poised for expansion, with an anticipated value of 4.74 USD Billion by 2035. This awareness not only influences prescribing practices but also encourages research and development efforts aimed at optimizing Daptomycin's applications in clinical settings.

Innovations in pharmaceutical technology are facilitating the development of new formulations and delivery methods for Daptomycin, thereby enhancing its therapeutic profile. The Global Daptomycin Market Industry benefits from these advancements, which may lead to improved patient outcomes and adherence to treatment regimens. As a result, the market is projected to grow at a CAGR of 3.28% from 2025 to 2035. These technological improvements not only optimize the drug's efficacy but also expand its potential applications, further driving market growth.

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Daptomycin market area will dominate this market, owing to increased research & development. In addition, the growing several government initiatives will boost the market growth in this region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 DAPTOMYCIN MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's Daptomycin market accounts for the second-largest market share due to the approval of Cubicin medicine by expanding market authorization. Further, the German Daptomycin market held the largest market share, and the UK Daptomycin market was the fastest-growing market in the European region.

The Asia-Pacific Daptomycin Market is expected to grow at the fastest CAGR from 2024 to 2032 due to the rising development of pharmaceutical and healthcare facilities and research. Moreover, China’s Daptomycin market held the largest market share, and the Indian Daptomycin market was the fastest-growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development to expand their product lines, which will help the Daptomycin market, grow even more. Market participants are also undertaking several strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, acquisition and mergers, higher investments, and collaboration with other organizations. The Daptomycin industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Daptomycin industry to benefit clients and increase the market sector. In recent years, the Daptomycin industry has offered some of the most significant advantages to medicine. Major players in the Daptomycin market, including Teva Pharmaceuticals Industries Ltd., Merck & Co., Cipla, Pfizer, BE Pharmaceuticals, Reddy’s Laboratories, Mylan, Fresenius Kabi, Nichi-Iko Pharmaceuticals, Novo Holdings A/S, Zhejiang Hisun, and others, are attempting to increase market demand by investing in research and development operations.

Sandoz is a market leader in generic pharmaceuticals and biosimilars, a part of the Novartis Group. By developing innovative strategies to make high-quality medicine more widely available, Sandoz helps society meet the growing need for healthcare. The company aims to become the world's most prestigious and successful generics firm. Sandoz’s  portfolio, comprising about 1000 compounds and covering a wide spectrum of therapeutic areas, is expected to generate $ 9.2 billion in sales by 2022.

Sandoz’s extensive selection results in large and recurring savings for patients and payors, ensuring the viability of healthcare systems in the face of severe financial demands and feeling up cash for cutting-edge medications. Every year, the company’s products are used by over 500 million patients. Sandoz’s comprehensive portfolio is driven by its leading  positions in generic antibiotics, the cornerstone of international healthcare systems, and biosimilars, the “cutting edge” off-patient medications. The company also carries out several focused corporate responsibility initiatives.  For Instance In July 2020, Snadoz released an AP-rated generic version of Cubicin and Daptomycin for injectable 500mg.

These injections are used to treat adults with complicated skin and skin structure infections (cSSSI) brought on by Gram-positive bacteria and certain bloodstream infections, such as right-sided infective endocarditis.